<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073653</url>
  </required_header>
  <id_info>
    <org_study_id>202110113</org_study_id>
    <nct_id>NCT05073653</nct_id>
  </id_info>
  <brief_title>A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer</brief_title>
  <official_title>A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with primary low and intermediate risk prostate cancer (PCa) for whom radical&#xD;
      prostatectomy are indicated, will be invited to participate to the present study.&#xD;
&#xD;
      The aim of this study is to investigate the clinical value of 68Ga-GRP positron emission&#xD;
      tomography / computed tomography (PET/CT) compared to 68Ga-PSMA PET/CT in patients with low&#xD;
      and intermediate risk PCa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer (PCa) is the second-most common cancer among men across the world, and a&#xD;
      significant cause of death in many regions. Different stages of PCa directly affect both the&#xD;
      therapeutic schedule and patient prognosis.&#xD;
&#xD;
      Recommended imaging modalities for initial staging include computerized tomography (CT) scan,&#xD;
      bone scan, and Magnetic Resonance Imaging (MRI). In addition to initial work-up, Gallium-68&#xD;
      prostate-specific membrane antigen positron emission tomography/computer tomography&#xD;
      (68Ga-PSMA PET/CT) is a relatively new nuclear imaging modality, showing high sensitivity and&#xD;
      specificity. Recently, several studies have investigated the role of 68Ga-PSMA PET/CT in a&#xD;
      first-line diagnostic setting, especially in patients with high-risk and biochemically&#xD;
      recurrent PCa.&#xD;
&#xD;
      Therefore, PET imaging with 68Ga-PSMA may participate to optimize work-up in the staging of&#xD;
      high-risk patients.&#xD;
&#xD;
      Another family of radiopharmaceuticals aimed to target the Gastrin-Releasing Peptide Receptor&#xD;
      (GRP-R) which is overexpressed in early stage PCa. Various radiolabeled GRP analogues have&#xD;
      been developed and shown encouraging results as related to the detection of primary PCa in&#xD;
      preclinical study. However, 68Ga-GRP failed to detect some bone metastases in&#xD;
      hormone-refractory patients. A prospective study identified that GRPR expression is not&#xD;
      associated with Gleason score (GS) and PSMA expression, suggesting that 68Ga-GRP and&#xD;
      68Ga-PSMA PET/CT may be complementary in various risks of PCa diagnosis.&#xD;
&#xD;
      The aim of this pilot study is to compare 68Ga-PSMA PET/CT to 68Ga-GRP PET/CT in patients&#xD;
      with PCa of low and intermediate risk to better understand how 68Ga-PSMA and 68Ga-GRP PET/CT&#xD;
      could performed a primary lesion mapping and how 68Ga-PSMA and 68Ga-GRP PET/CT could be used&#xD;
      (or combined) in clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 11, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Standardized Uptake Value (SUV)</measure>
    <time_frame>Day 0 (inclusion) or Day 2 to 21</time_frame>
    <description>Median Standardized Uptake Value (SUV) of 68Ga-GRP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Standardized Uptake Value (SUV)</measure>
    <time_frame>Day 0 (inclusion) or Day 2 to 21</time_frame>
    <description>Median Standardized Uptake Value (SUV) of 68Ga-PSMA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gleason score of lesion reported from pathological findings</measure>
    <time_frame>Day 3 to 60</time_frame>
    <description>Gleason score was used to rank prostate cancer risk and was associated with SUV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoreactive of lesion</measure>
    <time_frame>Day 3 to 60</time_frame>
    <description>Immunoreactive analysis of PSMA and GRPR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation analysis between SUV and Gleason score</measure>
    <time_frame>Day 3 to 60</time_frame>
    <description>Correlation analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-PSMA PET/CT Imaging</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Injection of the radioligand 68Ga-PSMA; Device: PET/CT; Following injection of 68Ga-PSMA, the participants will be subjected to whole body PET/CT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68Ga-GRP PET/CT Imaging</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Injection of the radioligand 68Ga-GRP; Device: PET/CT; Following injection of 68Ga-GRP, the participants will be subjected to whole body PET/CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-PSMA PET/CT</intervention_name>
    <description>Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy</description>
    <arm_group_label>68Ga-PSMA PET/CT Imaging</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-GRP PET/CT</intervention_name>
    <description>Exploratory, Single-institution Study, Comparing 68Ga-GRP PET/CT Versus 68Ga-PSMA PET/CT in Patients Diagnosed With Prostate Cancer of Low and Intermediate Risk for Radical Prostatectomy</description>
    <arm_group_label>68Ga-GRP PET/CT Imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients divided in :&#xD;
&#xD;
               -  Patients with low risk prostate cancer (Gleason score ≤ 6 and cT1-T2a and&#xD;
                  Prostate Specific Antigen (PSA) value &lt; 10 ng/mL);&#xD;
&#xD;
               -  Patients with intermediate risk prostate cancer (Gleason score 7 or cT2b or PSA&#xD;
                  value 10-20 ng/mL);&#xD;
&#xD;
               -  Patients with high risk prostate cancer (Gleason &gt; 7 or cT2c or PSA value &gt; 20&#xD;
                  ng/mL);&#xD;
&#xD;
               -  Candidate for radical prostatectomy after discussion in multidisciplinary&#xD;
                  committee;&#xD;
&#xD;
               -  Written informed consent willingly obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any kind of previous treatment for prostate cancer (hormonal treatment, EBRT,&#xD;
             brachytherapy, cryotherapy, etc…);&#xD;
&#xD;
          -  Patient not candidate for radical prostatectomy and/or unable to benefit from surgery;&#xD;
&#xD;
          -  Patient under legal protection or unable to express its own consent;&#xD;
&#xD;
          -  Patient within exclusion period from another clinical trial;&#xD;
&#xD;
          -  Claustrophobia (unable to accept PET/CT scanning).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuo Hu, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of PET Center,Xiangya Hospital,Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuo Hu, PhD, MD</last_name>
    <phone>+86 15874210819</phone>
    <email>hushuo_xy@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongxiang Tang, PhD, MD</last_name>
    <phone>+86 13549654360</phone>
    <email>xyyf0401@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of PET Center,Xiangya Hospital,Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>41008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongxiang Tang, PhD, MD</last_name>
      <phone>13549654360</phone>
      <email>xyyf0401@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12. Erratum in: CA Cancer J Clin. 2021 Jul;71(4):359.</citation>
    <PMID>33433946</PMID>
  </results_reference>
  <results_reference>
    <citation>Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712. Review.</citation>
    <PMID>29801018</PMID>
  </results_reference>
  <results_reference>
    <citation>Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020 Apr;77(4):403-417. doi: 10.1016/j.eururo.2019.01.049. Epub 2019 Feb 14.</citation>
    <PMID>30773328</PMID>
  </results_reference>
  <results_reference>
    <citation>Mansi R, Fleischmann A, Mäcke HR, Reubi JC. Targeting GRPR in urological cancers--from basic research to clinical application. Nat Rev Urol. 2013 Apr;10(4):235-44. doi: 10.1038/nrurol.2013.42. Epub 2013 Mar 19. Review.</citation>
    <PMID>23507930</PMID>
  </results_reference>
  <results_reference>
    <citation>Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men. Theranostics. 2014 Feb 1;4(4):412-9. doi: 10.7150/thno.7324. eCollection 2014.</citation>
    <PMID>24578724</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, Wu H, Zhu Z, Li F, Chen X. PET Using a GRPR Antagonist (68)Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients. J Nucl Med. 2018 Jun;59(6):922-928. doi: 10.2967/jnumed.117.198929. Epub 2017 Nov 9.</citation>
    <PMID>29123014</PMID>
  </results_reference>
  <results_reference>
    <citation>Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. Eur Urol Oncol. 2019 Mar;2(2):166-173. doi: 10.1016/j.euo.2018.08.011. Epub 2018 Sep 22.</citation>
    <PMID>31017093</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>68Ga-GRP PET/CT</keyword>
  <keyword>68Ga-PSMA PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

